 Jason Kolfenbach
Concepts (118)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Rheumatology | 7 | 2023 | 89 | 1.820 |
Why?
| | Rheumatic Diseases | 3 | 2023 | 49 | 1.030 |
Why?
| | Arthritis, Rheumatoid | 9 | 2023 | 1002 | 0.970 |
Why?
| | Autoimmune Diseases | 2 | 2019 | 392 | 0.820 |
Why?
| | Triage | 1 | 2019 | 192 | 0.560 |
Why?
| | Autoantibodies | 6 | 2015 | 1354 | 0.470 |
Why?
| | Connective Tissue Diseases | 1 | 2011 | 71 | 0.360 |
Why?
| | Myelitis | 1 | 2011 | 88 | 0.350 |
Why?
| | Hydrolases | 1 | 2010 | 51 | 0.350 |
Why?
| | Neuromyelitis Optica | 1 | 2011 | 115 | 0.350 |
Why?
| | Antirheumatic Agents | 2 | 2023 | 255 | 0.340 |
Why?
| | Granulomatosis with Polyangiitis | 2 | 2020 | 41 | 0.340 |
Why?
| | Family Health | 1 | 2009 | 194 | 0.310 |
Why?
| | Peptides, Cyclic | 5 | 2015 | 254 | 0.300 |
Why?
| | Rheumatoid Factor | 4 | 2015 | 157 | 0.280 |
Why?
| | Curriculum | 4 | 2023 | 845 | 0.250 |
Why?
| | Education, Medical, Graduate | 3 | 2023 | 374 | 0.250 |
Why?
| | Telemedicine | 2 | 2023 | 665 | 0.240 |
Why?
| | Keratoconjunctivitis Sicca | 1 | 2022 | 4 | 0.210 |
Why?
| | Corneal Ulcer | 1 | 2022 | 14 | 0.210 |
Why?
| | Scleritis | 1 | 2022 | 18 | 0.210 |
Why?
| | Genetic Predisposition to Disease | 2 | 2012 | 2102 | 0.210 |
Why?
| | Methotrexate | 3 | 2021 | 228 | 0.200 |
Why?
| | Rheumatologists | 2 | 2023 | 12 | 0.190 |
Why?
| | Educational Status | 1 | 2023 | 409 | 0.190 |
Why?
| | Autoimmunity | 3 | 2012 | 818 | 0.190 |
Why?
| | Aftercare | 1 | 2021 | 187 | 0.170 |
Why?
| | Retinal Diseases | 1 | 2020 | 76 | 0.170 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2021 | 221 | 0.160 |
Why?
| | Patient Selection | 2 | 2019 | 642 | 0.150 |
Why?
| | Humans | 21 | 2023 | 114937 | 0.150 |
Why?
| | Behcet Syndrome | 1 | 2016 | 17 | 0.140 |
Why?
| | Ophthalmologists | 1 | 2016 | 12 | 0.140 |
Why?
| | Patient Readmission | 1 | 2021 | 608 | 0.140 |
Why?
| | Azathioprine | 1 | 2016 | 49 | 0.140 |
Why?
| | Arthritis, Juvenile | 1 | 2016 | 42 | 0.130 |
Why?
| | Eye Diseases | 1 | 2016 | 76 | 0.130 |
Why?
| | Drug Costs | 1 | 2016 | 91 | 0.130 |
Why?
| | Glucocorticoids | 2 | 2016 | 534 | 0.120 |
Why?
| | Vision Disorders | 1 | 2016 | 130 | 0.120 |
Why?
| | Uveitis | 1 | 2016 | 115 | 0.120 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2020 | 525 | 0.120 |
Why?
| | Quality Improvement | 1 | 2021 | 954 | 0.120 |
Why?
| | Disease Progression | 2 | 2011 | 2392 | 0.110 |
Why?
| | Health Care Costs | 1 | 2016 | 380 | 0.100 |
Why?
| | Internship and Residency | 1 | 2022 | 944 | 0.100 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 1361 | 0.100 |
Why?
| | Adult | 9 | 2021 | 30608 | 0.100 |
Why?
| | Bronchial Diseases | 1 | 2011 | 38 | 0.100 |
Why?
| | C-Reactive Protein | 2 | 2012 | 362 | 0.090 |
Why?
| | Middle Aged | 8 | 2021 | 26806 | 0.090 |
Why?
| | Chemokines | 1 | 2012 | 213 | 0.090 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2013 | 797 | 0.090 |
Why?
| | Practice Patterns, Physicians' | 2 | 2016 | 1177 | 0.090 |
Why?
| | Protein-Arginine Deiminases | 1 | 2010 | 16 | 0.090 |
Why?
| | Patient Care Planning | 1 | 2011 | 139 | 0.090 |
Why?
| | Female | 11 | 2021 | 59581 | 0.090 |
Why?
| | Fellowships and Scholarships | 2 | 2023 | 227 | 0.090 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 1 | 2009 | 46 | 0.080 |
Why?
| | Male | 9 | 2021 | 55663 | 0.080 |
Why?
| | Lung Neoplasms | 1 | 2020 | 2223 | 0.070 |
Why?
| | Risk Factors | 3 | 2023 | 8637 | 0.070 |
Why?
| | Predictive Value of Tests | 1 | 2010 | 1801 | 0.060 |
Why?
| | Aged | 5 | 2021 | 19122 | 0.060 |
Why?
| | Lung Diseases | 1 | 2011 | 703 | 0.060 |
Why?
| | Inflammation | 2 | 2012 | 2485 | 0.060 |
Why?
| | Cohort Studies | 2 | 2012 | 4903 | 0.060 |
Why?
| | Longitudinal Studies | 1 | 2011 | 2382 | 0.060 |
Why?
| | Biological Factors | 1 | 2022 | 36 | 0.050 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2009 | 1893 | 0.050 |
Why?
| | Prospective Studies | 2 | 2012 | 6218 | 0.050 |
Why?
| | Immunosuppressive Agents | 2 | 2016 | 648 | 0.050 |
Why?
| | Young Adult | 2 | 2021 | 10478 | 0.050 |
Why?
| | Accreditation | 1 | 2022 | 78 | 0.050 |
Why?
| | Needs Assessment | 1 | 2023 | 315 | 0.050 |
Why?
| | Contraceptive Agents | 1 | 2021 | 54 | 0.040 |
Why?
| | Oximes | 1 | 2020 | 19 | 0.040 |
Why?
| | Time Factors | 1 | 2010 | 6125 | 0.040 |
Why?
| | Fluorescein Angiography | 1 | 2020 | 102 | 0.040 |
Why?
| | Internal Medicine | 1 | 2022 | 211 | 0.040 |
Why?
| | Sensitivity and Specificity | 2 | 2015 | 1700 | 0.040 |
Why?
| | Biomarkers | 1 | 2009 | 3418 | 0.040 |
Why?
| | Contraception | 1 | 2021 | 117 | 0.040 |
Why?
| | Transplantation, Autologous | 1 | 2020 | 176 | 0.040 |
Why?
| | Pyrimidinones | 1 | 2020 | 88 | 0.040 |
Why?
| | Rituximab | 1 | 2020 | 151 | 0.040 |
Why?
| | Amino Acid Substitution | 1 | 2020 | 262 | 0.040 |
Why?
| | Adolescent | 2 | 2021 | 17829 | 0.040 |
Why?
| | Pyridones | 1 | 2020 | 124 | 0.040 |
Why?
| | Imidazoles | 1 | 2020 | 211 | 0.040 |
Why?
| | United States | 2 | 2016 | 12211 | 0.040 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2020 | 193 | 0.040 |
Why?
| | Administration, Topical | 1 | 2016 | 139 | 0.030 |
Why?
| | Specialization | 1 | 2016 | 115 | 0.030 |
Why?
| | Clinical Competence | 1 | 2022 | 901 | 0.030 |
Why?
| | Ophthalmology | 1 | 2016 | 77 | 0.030 |
Why?
| | Surveys and Questionnaires | 2 | 2016 | 4635 | 0.030 |
Why?
| | Pandemics | 1 | 2022 | 1325 | 0.030 |
Why?
| | Immunoglobulins | 1 | 2015 | 143 | 0.030 |
Why?
| | Health Care Surveys | 1 | 2016 | 539 | 0.030 |
Why?
| | Insurance, Health | 1 | 2016 | 244 | 0.030 |
Why?
| | Clinical Decision-Making | 1 | 2016 | 269 | 0.030 |
Why?
| | Interleukin-9 | 1 | 2012 | 10 | 0.030 |
Why?
| | Arthrography | 1 | 2011 | 22 | 0.020 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2012 | 140 | 0.020 |
Why?
| | Patient Care Team | 1 | 2016 | 516 | 0.020 |
Why?
| | Joints | 1 | 2011 | 84 | 0.020 |
Why?
| | Interleukin-2 | 1 | 2012 | 419 | 0.020 |
Why?
| | Decision Making | 1 | 2016 | 781 | 0.020 |
Why?
| | Pregnancy | 1 | 2021 | 5527 | 0.020 |
Why?
| | Interferon-gamma | 1 | 2012 | 723 | 0.020 |
Why?
| | Interleukin-6 | 1 | 2012 | 676 | 0.020 |
Why?
| | Logistic Models | 1 | 2012 | 1844 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2020 | 9105 | 0.020 |
Why?
| | Retrospective Studies | 1 | 2021 | 12544 | 0.020 |
Why?
| | Cytokines | 1 | 2012 | 1843 | 0.020 |
Why?
| | Phenotype | 1 | 2012 | 2817 | 0.010 |
Why?
| | Child | 1 | 2016 | 18366 | 0.010 |
Why?
|
|
Kolfenbach's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|